Maintaining surgical treatment of non-small cell lung cancer during the COVID-19 pandemic in Paris

Publication date: Available online 8 October 2020Source: The Annals of Thoracic SurgeryAuthor(s): Jean-Baptiste Leclère, Ludovic Fournel, Harry Etienne, Charbel Al Zreibi, Ilaria Onorati, Arnaud Roussel, Yves Castier, Emmanuel Martinod, Françoise Le Pimpec-Barthes, Marco Alifano, Jalal Assouad, Pierre Mordant, thoracic surgery units of Paris Public Hospitals.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research

Related Links:

Surgical resection is the standard-of-care approach for early-stage non-small cell lung cancer (NSCLC). Surgery is also considered an acceptable standard infit patients with oligometastatic lesions in the lungs. The COVID-19 pandemic has led to worldwide issues with access to operating room time, with patients and physicians facing uncertainty as to when surgical resection will be available, with likely delays of months. Further compounding this are concerns about increased risks of respiratory complications with lung cancer surgery during active phases of the pandemic. In this setting, many thoracic oncology teams are emb...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Since February 21, 2020, when the first Italian patient was admitted to the hospital due to severe coronavirus disease 2019 (COVID-19) and found positive to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this infection has spread through Italy, quickly becoming the largest COVID-19 outbreak outside Asia [1]. On March 12th, the World Health Organisation (WHO) declared COVID-19 a pandemic, placing the WHO European Region at the centre of the pandemic. Elderly people and those with pre-existing health conditions are most at risk of life-threatening complications [2].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
Madam — Recent Royal College of Radiologists' treatment guidelines for lung cancer during the COVID-19 pandemic [1] motivated us to share the findings of our recent audit of accelerated hypofractionated concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC; SOCCAR regime n): 55 Gy in 20 fractions over 26 days with concomitant chemotherapy (cisplatin and vinorelbine) [2].
Source: Clinical Oncology - Category: Radiology Authors: Tags: Letter Source Type: research
Source: Clinical Oncology - Category: Radiology Authors: Tags: Letter Source Type: research
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Chris Arendt, Ph.D., a leader of Takeda’s oncology team to discuss how the company is ensuring cancer research and medicines continue to benefit patients in the age of COVID-19.“The new normal” has been used to describe the challenging and dy...
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: PhRMA Member Company Cancer Coronavirus Source Type: news
Immune checkpoint inhibitors (ICPIs) have revolutionized the management and prognosis of fit patients with advanced non-small cell lung cancer (NSCLC). Recently, the publication of 5-year survival rates has cemented to role of ICPIs in NSCLC. An ongoing challenge is to determine the optimal treatment duration to find the balance between efficacy, toxicity and cost. From the onset of ICPI trials, different durations were used, ranging from treatment until progression or toxicity, to fixed durations of 2 years. Subsequently, exploratory analyses from a 1-year fixed duration trial failed to change practice. There are, to date...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: There was consensus that during the COVID-19 pandemic it is appropriate to defer enrollment in lung cancer screening and modify the evaluation of lung nodules due to the added risks from potential exposure and the need for resource reallocation. There are multiple local, regional, and patient related factors that should be considered when applying these statements to individual patient care. PMID: 32335067 [PubMed - as supplied by publisher]
Source: Chest - Category: Respiratory Medicine Authors: Tags: Chest Source Type: research
New Brunswick, N.J. (April 14, 2020) – Johnson &Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share. “With Johnson &Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” said ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
More News: Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | COVID-19 | Hospitals | Lung Cancer | Non-Small Cell Lung Cancer | Pandemics